Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor gene syndrome due to germline mutations in either TSC1 or TSC2. 10–15% of TSC individuals have no mutation identified (NMI) after thorough conventional molecular diagnostic assessment. 53 TSC subjects who were NMI were studied using next generation sequencing to search for mutations in these genes. Blood/saliva DNA including parental samples were available from all subjects, and skin tumor biopsy DNA was available from six subjects. We identified mutations in 45 of 53 subjects (85%). Mosaicism was observed in the majority (26 of 45, 58%), and intronic mutations were also unusually common, seen in 18 of 45 subjects (40%). Seventeen (38%) mutations were seen at an allele frequency < 5%, five at an allele frequency < 1%, and two were identified in skin tumor biopsies only, and were not seen at appreciable frequency in blood or saliva DNA. These findings illuminate the extent of mosaicism in TSC, indicate the importance of full gene coverage and next generation sequencing for mutation detection, show that analysis of TSC-related tumors can increase the mutation detection rate, indicate that it is not likely that a third TSC gene exists, and enable provision of genetic counseling to the substantial population of TSC individuals who are currently NMI.
Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–54. Epub 2013/09/24. doi: 10.1016/j.pediatrneurol.2013.08.001. pmid:24053982
[5]
Ali M, Girimaji SC, Markandaya M, Shukla AK, Sacchidanand S, Kumar A. Mutation and polymorphism analysis of TSC1 and TSC2 genes in Indian patients with tuberous sclerosis complex. Acta Neurol Scand. 2005;111(1):54–63. pmid:15595939 doi: 10.1111/j.1600-0404.2004.00366.x
[6]
Apak A, Haliloglu G, Kose G, Yilmaz E, Anlar B, Aysun S. Mutation analysis of TSC2 gene in 33 Turkish familial cases with tuberous sclerosis. Turk J Pediatr. 2003;45(1):1–5. pmid:12718362
[7]
Au K- S, Rodriguez JA, Finch JL, Volcik KA, Roach ES, Delgado MR, et al. Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet. 1998;62:286–94. pmid:9463313 doi: 10.1086/301705
[8]
Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9(2):88–100. pmid:17304050 doi: 10.1097/gim.0b013e31803068c7
[9]
Choi JE, Chae JH, Hwang YS, Kim KJ. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex. Brain Dev. 2006;28(7):440–6. pmid:16554133 doi: 10.1016/j.braindev.2006.01.006
[10]
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. Am J Hum Genet. 2001;68(1):64–80. pmid:11112665 doi: 10.1086/316951
[11]
Hung CC, Su YN, Chien SC, Liou HH, Chen CC, Chen PC, et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet. 2006;7:72. pmid:16981987
[12]
Langkau N, Martin N, Brandt R, Zugge K, Quast S, Wiegele G, et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios. Eur J Pediatr. 2002;161(7):393–402. pmid:12111193 doi: 10.1007/s00431-001-0903-7
[13]
Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, et al. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat. 1999;14(5):412–22. pmid:10533067 doi: 10.1002/(sici)1098-1004(199911)14:5<412::aid-humu7>3.0.co;2-k
[14]
Rendtorff ND, Bjerregaard B, Frodin M, Kjaergaard S, Hove H, Skovby F, et al. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Hum Mutat. 2005;26(4):374–83. pmid:16114042 doi: 10.1002/humu.20227
[15]
Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype—phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13(6):731–41. pmid:15798777 doi: 10.1038/sj.ejhg.5201402
[16]
van Slegtenhorst M, Verhoef S, Tempelaars A, Bakker L, Wang Q, Wessels M, et al. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J Med Genet. 1999;36(4):285–9. pmid:10227394
[17]
Yamashita Y, Ono J, Okada S, Wataya-Kaneda M, Yoshikawa K, Nishizawa M, et al. Analysis of all exons of TSC1 and TSC2 genes for germline mutations in Japanese patients with tuberous sclerosis: report of 10 mutations. Am J Med Genet. 2000;90(2):123–6. pmid:10607950 doi: 10.1002/(sici)1096-8628(20000117)90:2<123::aid-ajmg7>3.3.co;2-c
[18]
Chromosome European 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–15. doi: 10.1016/0092-8674(93)90618-z
[19]
Sampson JR, Scahill SJ, Stephenson JB, Mann L, Connor JM. Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet. 1989;26(1):28–31. pmid:2918523 doi: 10.1136/jmg.26.1.28
[20]
van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–8. pmid:9242607 doi: 10.1126/science.277.5327.805
[21]
Camposano SE, Greenberg E, Kwiatkowski DJ, Thiele EA. Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified. Ann Hum Genet. 2009;73(2):141–6. doi: 10.1111/j.1469-1809.2008.00496.x. pmid:19133941
[22]
Boronat S, Shaaya EA, Doherty CM, Caruso P, Thiele EA. Tuberous sclerosis complex without tubers and subependymal nodules: a phenotype-genotype study. Clin Genet. 2014;86(2):149–54. doi: 10.1111/cge.12245. pmid:23909698
[23]
Tyburczy ME, Wang JA, Li S, Thangapazham R, Chekaluk Y, Moss J, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23(8):2023–9. doi: 10.1093/hmg/ddt597. pmid:24271014
[24]
Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, et al. Comprehensive Mutation Analysis of TSC1 and TSC2-and Phenotypic Correlations in 150 Families with Tuberous Sclerosis. Am J Hum Genet. 1999;64(5):1305–15. pmid:10205261 doi: 10.1086/302381
[25]
Young JM, Burley MW, Jeremiah SJ, Jeganathan D, Ekong R, Osborne JP, et al. A mutation screen of the TSC1 gene reveals 26 protein truncating mutations and 1 splice site mutation in a panel of 79 tuberous sclerosis patients. Ann Hum Genet. 1998;62(Pt 3):203–13. pmid:9803264 doi: 10.1046/j.1469-1809.1998.6230203.x
[26]
Mayer K, Ballhausen W, Leistner W, Rott H. Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochim Biophys Acta. 2000;1502(3):495–507. pmid:11068191 doi: 10.1016/s0925-4439(00)00072-7
[27]
Povey S, Ekong R. Tuberous sclerosis database. .
[28]
Jeganathan D, Fox MF, Young JM, Yates JR, Osborne JP, Povey S. Nonsense-mediated RNA decay in the TSC1 gene suggests a useful tool pre- and post-positional cloning. Hum Genet. 2002;111(6):555–65. pmid:12436247 doi: 10.1007/s00439-002-0821-4
[29]
King K, Flinter FA, Nihalani V, Green PM. Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet. 2002;111(6):548–54. pmid:12436246 doi: 10.1007/s00439-002-0830-3
[30]
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393(6686):702–5. pmid:9641683
[31]
Harland M, Mistry S, Bishop DT, Bishop JA. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet. 2001;10(23):2679–86. pmid:11726555 doi: 10.1093/hmg/10.23.2679
[32]
Nellist M, Brouwer RW, Kockx CE, van Veghel-Plandsoen M, Withagen-Hermans C, Prins-Bakker L, et al. Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet. 2015;16:10. doi: 10.1186/s12881-015-0155-4. pmid:25927202
[33]
Mayer K, Ballhausen W, Rott HD. Mutation screening of the entire coding regions of the TSC1 and the TSC2 gene with the protein truncation test (PTT) identifies frequent splicing defects. Hum Mutat. 1999;14(5):401–11. pmid:10533066 doi: 10.1002/(sici)1098-1004(199911)14:5<401::aid-humu6>3.0.co;2-r
[34]
Kwiatkowska J, Wigowska-Sowinska J, Napierala D, Slomski R, Kwiatkowski DJ. Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. N Engl J Med. 1999;340(9):703–7. pmid:10053179 doi: 10.1056/nejm199903043400905
[35]
Rose VM, Au KS, Pollom G, Roach ES, Prashner HR, Northrup H. Germ-Line Mosaicism in Tuberous Sclerosis: How Common? Am J Hum Genet. 1999;64(4):986–92. pmid:10090883 doi: 10.1086/302322
[36]
Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997;61(4):843–51. pmid:9382094 doi: 10.1086/514888
[37]
Jones AC, Sampson JR, Cheadle JP. Low level mosaicism detectable by DHPLC but not by direct sequencing. Hum Mutat. 2001;17(3):233–4. pmid:11241845 doi: 10.1002/humu.8
[38]
Emmerson P, Maynard J, Jones S, Butler R, Sampson JR, Cheadle JP. Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat. 2003;21(2):112–5. pmid:12552557 doi: 10.1002/humu.10159
[39]
Verhoef S, Bakker L, Tempelaars AM, Hesseling-Janssen AL, Mazurczak T, Jozwiak S, et al. High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet. 1999;64(6):1632–7. pmid:10330349 doi: 10.1086/302412
[40]
Yates JR, van Bakel I, Sepp T, Payne SJ, Webb DW, Nevin NC, et al. Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet. 1997;6(13):2265–9. pmid:9361032 doi: 10.1093/hmg/6.13.2265
[41]
Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet. 2007;121(3–4):389–400. pmid:17287951 doi: 10.1007/s00439-006-0308-9
[42]
Verhoef S, Vrtel R, van ET, Bakker L, Sikkens E, Halley D, et al. Somatic mosaicism and clinical variation in tuberous sclerosis complex. Lancet. 1995;345(8943):202. pmid:7823706 doi: 10.1016/s0140-6736(95)90213-9
[43]
Roberts PS, Dabora S, Thiele EA, Franz DN, Jozwiak S, Kwiatkowski DJ. Somatic mosaicism is rare in unaffected parents of patients with sporadic tuberous sclerosis. J Med Genet. 2004;41(5):e69. pmid:15121797 doi: 10.1136/jmg.2003.014126
[44]
Sampson JR. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans. 2003;31(Pt 3):592–6. pmid:12773162 doi: 10.1042/bst0310592
[45]
Qin W, Kozlowski P, Taillon BE, Bouffard P, Holmes AJ, Janne P, et al. Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex. Hum Genet. 2010;127(5):573–82. Epub 2010/02/19. doi: 10.1007/s00439-010-0801-z. pmid:20165957
[46]
Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet. 2007;44(7):424–8. pmid:17307835 doi: 10.1136/jmg.2006.047753
[47]
Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40(2):109–14. pmid:12566519 doi: 10.1136/jmg.40.2.109
[48]
Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35(6):450–5. pmid:9643284 doi: 10.1136/jmg.35.6.450
[49]
Tyburczy ME, Jozwiak S, Malinowska IA, Chekaluk Y, Pugh TJ, Wu CL, et al. A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet. 2015;24(7):1836–42. doi: 10.1093/hmg/ddu597. pmid:25432535
[50]
Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589–95. Epub 2010/01/19. doi: 10.1093/bioinformatics/btp698. pmid:20080505
[51]
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303. Epub 2010/07/21. doi: 10.1101/gr.107524.110. pmid:20644199
[52]
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9. Epub 2009/06/10. doi: 10.1093/bioinformatics/btp352. pmid:19505943
1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012;491:56–65 (01 November 2012). . doi: 10.1038/nature11632. pmid:23128226
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9. Epub 2010/04/01. doi: 10.1038/nmeth0410-248. pmid:20354512
[58]
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248–249. . doi: 10.1038/nmeth0410-248. pmid:20354512
[59]
Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863–74. Epub 2001/05/05 pmid:11337480 doi: 10.1101/gr.176601
[60]
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073–81. . doi: 10.1038/nprot.2009.86. pmid:19561590
